Daewoong (003090) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Daewoong stock KRW 48,300, price KRW 16,100, upside +200.0%, quality 50 out of 100. Rating: strongly undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 11,338 KRW – 46,550 KRW · fair‑value band 34,783 KRW – 61,635 KRW · the 16,100 KRW price screens below the 48,300 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Daewoong in your weekly email
Every Wednesday you see whether Daewoong is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea.
Show moreShow less
It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products.
The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Daewoong Co., Ltd. was founded in 1945 and is headquartered in Seongnam-si, South Korea.
Stock analysis
Daewoong (003090) currently trades at 16,100 KRW, while our model-based Fair Value estimate is 48,300 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 74,745 KRW per share, and 13 of the 16 models we run sit above the 16,100 KRW price.
Bear case: the Asset-Based group reads lowest at 12,698 KRW, and 3 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: 34,783 KRW (bear) to 61,635 KRW (bull), the price of 16,100 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Daewoong reported revenue of 2.1T KRW in FY2025 versus 1.5T KRW in FY2021, a compound +8.2%/yr. Reported net income was 175B KRW in FY2025, compounding +22.1%/yr from FY2021.
Key figures
Market cap 658B KRW (≈ $487M) Small · P/E ratio 3.7 · P/S ratio 0.31 · EPS (TTM) 4,268 KRW · Dividend yield 1.2% · Net margin 8.5% · Return on equity 12.9% · Return on assets (EBIT) 9.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, 003090 screens cheaper than that median.
Fair Value models
Bear34,783 KRWFair Value 48,300 KRWBull61,635 KRW
Price 16,100 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3,488 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.51/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Start year 2020 (pandemic). Over 10 years: +7.6% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +22.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+20.8%
Dividend (yield on the price)1.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17.7% vs 25.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 74% above its own trend.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)12.9% · Above median
Return on assets5.4% · Above median
Net margin (12 months)8.5% · Above median
Operating margin (12 months)13.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)8.0% · Above median
Dividend yield (12 months)1.2% · Below median
Balance sheet
Debt / equity0.47× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daewoong Fair Value". https://www.fairvalue-calculator.com/stock/003090
Frequently asked questions
Is Daewoong (003090) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 48,300 KRW versus a price of 16,100 KRW, about +200% upside (undervalued).
What is the fair value of 003090?
Our model-based fair value for Daewoong is 48,300 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 16,100 KRW.
What is the quality score of 003090?
Daewoong has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daewoong (003090)?
Our model-based price target is the fair value of 48,300 KRW (as of Nov 8, 2026) from 16 valuation models. Cautious scenario 34,783 KRW, optimistic scenario 61,635 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daewoong stock forecast for 2026?
Our models put fair value at 48,300 KRW, about +200% upside versus a price of 16,100 KRW (undervalued). Cautious scenario 34,783 KRW, optimistic scenario 61,635 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daewoong (003090)?
Daewoong reported trailing-twelve-month revenue of about 2.1T KRW (latest available figure, as of Nov 8, 2026).
Does Daewoong pay a dividend?
Daewoong currently shows a dividend yield of 1.24% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Daewoong (003090) and when is the ex-dividend date?
Daewoong pays a dividend of 200.00 KRW per share a year, a dividend yield of 1.2%. The last ex-dividend date was Dec 29, 2025. The payout ratio is 4.7% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Daewoong (003090)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daewoong it is 48,300 KRW per share (as of Nov 8, 2026), against a price of 16,100 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Daewoong stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 003090 trades below its calculated fair value: price 16,100 KRW, fair value 48,300 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003090?
No. The price is what the market pays today (16,100 KRW); the fair value is what the company's own numbers justify (48,300 KRW). For Daewoong the two are 32,200 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daewoong worth?
The market values Daewoong at about 658B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 16,100 KRW; our models calculate a fair value of 48,300 KRW per share.
What do the bullish and bearish scenarios say about 003090?
Our models span a range for Daewoong: cautious scenario 34,783 KRW, base 48,300 KRW, optimistic 61,635 KRW per share (as of Nov 8, 2026, price 16,100 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 003090?
Daewoong trades at a price-to-earnings ratio of 3.7 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 48,300 KRW is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 12.6. Other multiples: P/B 0.6, P/S 0.3, EV/EBITDA 3.0.
How solid is the balance sheet of Daewoong (003090)?
Balance-sheet figures for Daewoong (as of Nov 8, 2026): return on equity 12.9%, debt of 0.47 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 003090 from its 52-week high?
Daewoong trades at 16,100 KRW, about 45% below its 52-week high of 29,350 KRW and 11% above the low of 14,510 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 48,300 KRW is for.
Which stocks are comparable to Daewoong?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daewoong stock attractive at the current price?
The data as of Nov 8, 2026: price 16,100 KRW, calculated fair value 48,300 KRW (+200%), Quality Score 50/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003090 calculated?
We run Daewoong through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 48,300 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Daewoong currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daewoong (003090)?
The closing price on Nov 6, 2026 was 16,100 KRW. Our model-based fair value is 48,300 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daewoong right now?
The price is below even our cautious bear case (34,783 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Daewoong
How large is the market capitalisation of Daewoong (003090)?
The market capitalisation of Daewoong is 658B KRW (≈ $487M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daewoong (003090)?
The price-to-sales ratio of Daewoong is 0.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daewoong (003090)?
Earnings per share at Daewoong are 4,268 KRW (price ÷ EPS = P/E 3.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daewoong (003090)?
The dividend yield of Daewoong is 1.2% (payout 4.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daewoong (003090)?
The net margin of Daewoong is 8.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daewoong (003090)?
The return on equity (ROE) of Daewoong is 12.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daewoong (003090)?
On an EBIT basis the return on assets of Daewoong is 9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daewoong (003090)?
The operating margin of Daewoong is 13.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daewoong (003090)?
Revenue at Daewoong is growing +8.0% versus a year earlier (3y avg +6.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daewoong (003090)?
Earnings per share at Daewoong are growing −14.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daewoong (003090) generate?
The free cash flow of Daewoong is −90.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Daewoong (003090) carry?
The net debt of Daewoong is 619B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daewoong in the live analysis
One click puts Daewoong on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026